Results 151 to 160 of about 28,689 (318)
Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo [PDF]
, 2015 Christof Ebert +5 more
openalex +1 more source
Immunology, EarlyView.During homeostasis, CCL22 is secreted by dendritic cells (DC), which mediate contacts between regulatory T cells (Treg) and DC to maintain immune balance. Activation of innate immunity via microbes or pattern recognition receptor (PRR) agonists induces the secretion of several soluble factors (e.g., type I and II interferons, IL‐10), which mediate ...
Ignazio Piseddu +24 more
wiley +1 more source
Neural Regeneration ResearchThe inflammatory microenvironment and neurotoxicity can hinder neuronal regeneration and functional recovery after spinal cord injury. Ruxolitinib, a JAK-STAT inhibitor, exhibits effectiveness in autoimmune diseases, arthritis, and managing inflammatory ...
Jiang Cao +12 more
doaj +1 more source
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis [PDF]
, 2015 Michael W. Deininger +5 more
openalex +1 more source
Pharmacovigilance‐Based Identification and Mechanistic Exploration of Periodontitis‐Related Drugs
Journal of Clinical Periodontology, EarlyView.ABSTRACT Background Periodontitis is a common chronic inflammatory disease. However, drug‐related risks and underlying molecular mechanisms remain underexplored from large real‐world data. Methods We first mined the US Food and Drug Administration Adverse Event Reporting System (FAERS) database to identify drugs disproportionately associated with ...
Wuda Huoshen +11 more
wiley +1 more source
Clinical heterogeneity in vitiligo: Identification of clinical markers based patient clusters
Journal of the European Academy of Dermatology and Venereology, EarlyView.Vitiligo is a chronic autoimmune disease with heterogeneous clinical presentations. This study analysed 399 patients using hierarchical clustering and identified five phenotypes based on clinical characteristics and lesion distribution. Two groups exhibited high disease activity and extensive involvement.
Laura Galissi +8 more
wiley +1 more source
Targeting Ref-1/APE1 Pathway Inhibition in Pancreatic Cancer Using APX3330 for Clinical Trials [PDF]
, 2016 poster abstractPancreatic ductal adenocarcinoma is the 4th leading cause of cancer-related mortality in the US. Most patients present with advanced disease and ~95% die within five years, most surviving under six months.
Fishel, Melissa L. +6 more
core
Ruxolitinib cream for the treatment of vitiligo [PDF]
The Lancet, 2020 Vipawee S Chat +3 more
openaire +3 more sources